Related Experiment Video
Updated: Oct 13, 2025
Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
Association of COVID-19 with Rhino-Cerebral Mucormycosis: An Observational Study
Varsha Agarwal1, Ambika Gupta1, Virendra Singh2
1Dept. of Oral Medicine and Radiology, Post Graduate Institute of Dental Sciences, Room No. 11, Rohtak, 124001 India.
Abstract:
Mucormycosis is becoming more common in patients infected with or recovering from COVID-19 under the current situation. However, there is a scarcity of research on a specific group of COVID-19 individuals who are predisposed to mucormycosis. As a result, a retrospective observational study was undertaken to assess the possible connection of mucormycosis with COVID-19. The goal was also to investigate the link between diabetes mellitus, mucormycosis and COVID-19. The occurrence and severity of the disease among the case records were assessed using signs and symptoms, investigations conducted during COVID-19, and serological test results. Patients were classified as previously known diabetics, recently diagnosed diabetics, or non-diabetics based on their history of pre-existing DM and HBA1c levels at the time of reporting for mucormycosis. The findings show that mild COVID-19-infected patients and non-diabetic patients have a high incidence of COVID-19-associated mucormycosis (CAM). As a result, all clinicians participating in the care of COVID-infected patients must be aware of the significant risk of secondary mucormycosis in the post-recovery phase, even in those with mild or moderate symptoms.
Insights
COVID-19-associated mucormycosis (CAM) is increasingly observed. This study found a high incidence of CAM in mild COVID-19 and non-diabetic patients, highlighting a significant post-recovery risk.
Area of Science:
- Infectious Diseases
- Endocrinology
- Public Health
Background:
- Mucormycosis incidence is rising, particularly in COVID-19 patients.
- Limited research exists on specific COVID-19 patient groups at risk for mucormycosis.
- Understanding the interplay between COVID-19, diabetes mellitus, and mucormycosis is crucial.
Purpose of the Study:
- To investigate the association between COVID-19 and mucormycosis.
- To explore the link between diabetes mellitus, COVID-19, and mucormycosis.
- To identify patient subgroups predisposed to COVID-19-associated mucormycosis (CAM).
Main Methods:
- Retrospective observational study design.
- Analysis of patient records including signs, symptoms, and serological test results during COVID-19.
- Classification of patients into diabetic (pre-existing or newly diagnosed) and non-diabetic groups based on medical history and HbA1c levels.
Main Results:
- A significant incidence of COVID-19-associated mucormycosis (CAM) was observed in patients with mild COVID-19.
- Non-diabetic patients exhibited a high occurrence of CAM.
- The study identified a notable risk of secondary mucormycosis in the post-recovery phase of COVID-19.
Conclusions:
- Clinicians must be vigilant for secondary mucormycosis in all COVID-19 patients, including those with mild or moderate illness.
- The risk of CAM extends beyond severe COVID-19 cases and diabetic populations.
- Awareness of CAM risk in post-COVID-19 patients is essential for timely diagnosis and management.
More Related Videos
09:02Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions
Published on: September 22, 2023
07:26Intracranial Subarachnoidal Route of Infection for Investigating Roles of Streptococcus suis Biofilms in Meningitis in a Mouse Infection Model
Published on: July 1, 2018
